Journal Article

PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients

García-Closas, Montserrat, Margolin, Sara, Hopper, John L., Pharoah, Paul D. P., Hauptmann, Michael, Eccles, Diana M., Martinez, Maria Elena, Blomqvist, Carl, Lubiński, Jan, Bojesen, Stig E., Giardiello, Daniele, Heemskerk-Gerritsen, B. A. M., Nevanlinna, Heli, Chang-Claude, Jenny, Steyerberg, Ewout W., Hooning, Maartje J., Czene, Kamila, Haiman, Christopher A., Pelders, Saskia, Easton, Douglas F., Devilee, Peter, Siesling, Sabine, Camp, Nicola J., Hall, Per, Lindblom, Annika, Flyger, Henrik, Nevelsteen, Ines, Bolla, Manjeet K., Figueroa, Jonine D., Leeuwen, Floor E., van Hest, Liselotte P., Fasching, Peter A., Jakubowska, Anna, van der Hout, Annemieke H., Schmidt, Marjanka K., Southey, Melissa C., Becher, Heiko, Keeman, Renske, Hamann, Ute

2022

Overview

Background Prediction of contralateral breast cancer (CBC) risk is challenging due to moderate performances of the known risk factors. We aimed to improve our previous risk prediction model (PredictCBC) by updated follow-up and including additional risk factors. Methods We included data from 207,510 invasive breast cancer patients participating in 23 studies. In total, 8225 CBC events occurred over a median follow-up of 10.2 years. In addition to the previously included risk factors, PredictCBC-2.0 included CHEK2 c.1100delC, a 313 variant polygenic risk score (PRS-313), body mass index (BMI), and parity. Fine and Gray regression was used to fit the model. Calibration and a time-dependent area under the curve (AUC) at 5 and 10 years were assessed to determine the performance of the models. Decision curve analysis was performed to evaluate the net benefit of PredictCBC-2.0 and previous PredictCBC models. Results The discrimination of PredictCBC-2.0 at 10 years was higher than PredictCBC with an AUC of 0.65 (95% prediction intervals (PI) 0.56–0.74) versus 0.63 (95%PI 0.54–0.71). PredictCBC-2.0 was well calibrated with an observed/expected ratio at 10 years of 0.92 (95%PI 0.34–2.54). Decision curve analysis for contralateral preventive mastectomy (CPM) showed the potential clinical utility of PredictCBC-2.0 between thresholds of 4 and 12% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers. Conclusions Additional genetic information beyond BRCA1/2 germline mutations improved CBC risk prediction and might help tailor clinical decision-making toward CPM or alternative preventive strategies. Identifying patients who benefit from CPM, especially in the general breast cancer population, remains challenging.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Biomedical and Life Sciences / Biomedicine / Body mass index / BRCA1 protein / Breast cancer / Breast Cancer Association Consortium / Breast cancer genetic predisposition / Breast Neoplasms - diagnosis / Breast Neoplasms - epidemiology / Breast Neoplasms - genetics / Cancer / Cancer patients / Cancer Research / Clinical decision making / Contralateral breast cancer / Contralateral preventive mastectomy / Decision making / Female / Gene mutations / Germ-Line Mutation / Health aspects / Humans / Mastectomy / Mutation / Oncology / Oncology, Experimental / Patients / Prediction models / Prophylactic Mastectomy / Risk Factors / Risk prediction / Surgical Oncology / Womens health